The Board of the American Brachytherapy (ABS) supports the nomination of Radiation Oncologist Stephen Hahn, MD, FASTRO to be the next Commissioner of the Food and Drug Administration (FDA). Dr. Hahn is a renowned radiation oncologist known both for his innovative research and his focus on ensuring quality and safety in oncology. His expertise in novel therapeutics, complex medical devices, and health care administration make him an ideal candidate to lead the organization. Dr. Hahn is well known within the field of radiation oncology for his integrity as a leader and his dedication to delivering the highest quality patient care.
Throughout his career, Dr. Hahn has been a strong advocate for high quality brachytherapy treatment. Brachytherapy is a specialized form of radiation therapy used in the curative treatment of cervical, prostate and other cancers. ABS believes that Dr. Hahn is the ideal choice to lead the FDA and ensure the organization remains focused on its mission to protect public health.
About American Brachytherapy Society
The mission of the ABS is to benefit patients by providing information directly to the consumer, by promoting the highest possible standards of practice of brachytherapy, and to benefit health care professionals by encouraging improved and continuing education for radiation oncologists and other health care professionals involved in the treatment of cancer.
To learn more about ABS, visit
our
website
or on twitter @AmericanBrachy
